Discovery and Optimization of Benzotriazine Di-N-Oxides Targeting Replicating and Nonreplicating Mycobacterium tuberculosis
摘要:
Compounds bactericidal against both replicating and nonreplicating Mtb may shorten the length of TB treatment regimens by eliminating infections more rapidly. Screening of a panel of antimicrobial and anticancer drug classes that are bioreduced into cytotoxic species revealed that 1,2,4-benzotriazine di-N-oxides (BTOs) are potently bactericidal against replicating and nonreplicating Mtb. Medicinal chemistry optimization, guided by semiempirical molecular orbital calculations, identified a new lead compound (20q) from this series with an MIC of 0.31 mu g/mL against H37Rv and a cytotoxicity (CC50) against Vero cells of 25 mu g/mL. 20q also had equivalent potency against a panel of single-drug resistant strains of Mtb and remarkably selective activity for Mtb over a panel of other pathogenic bacterial strains. 20q was also negative in a L5178Y MOLY assay, indicating low potential for genetic toxicity. These data along with measurements of the physiochemical properties and pharmacokinetic profile demonstrate that BTOs have the potential to be developed into a new class of antitubercular drugs.
Synthesis, Structure and Hypoxic Cytotoxicity of 3-Amino-1,2,4-benzotriazine-1,4-dioxide Derivatives
作者:Faqin Jiang、Qinjie Weng、Rong Sheng、Qing Xia、Qiaojun He、Bo Yang、Yongzhou Hu
DOI:10.1002/ardp.200600201
日期:2007.5
3‐amino‐1,2,4‐benzotriazine‐1,4‐dioxide derivatives were synthesized and screened for their in vitro cytotoxicity against promyelocytic leukemia HL‐60, androgen‐independent prostate tumor PC3, hepatocellular carcinoma Bel‐7402, human esophagus tumor ECA‐109, and human breast tumor MCF‐7 cell lines in hypoxia and in normoxia. Most compounds showed higher cytotoxic activity both in hypoxia and in normoxia
Benzotriazine Oxides as Drugs Targeting Mycobacterium Tuberculosis
申请人:Madrid Peter
公开号:US20130150369A1
公开(公告)日:2013-06-13
Benzotriazine doxides are disclosed as drugs targeting
mycobacterium tuberculosis
, including novel compounds of formula I:
Benzotriazine doxides被披露为针对结核分枝杆菌的药物,包括公式I的新化合物。
BENZOTRIAZINE OXIDES AS DRUGS TARGETING MYCOBACTERIUM TUBERCULOSIS
申请人:Sri International Inc.
公开号:EP2800744A1
公开(公告)日:2014-11-12
US9663478B2
申请人:——
公开号:US9663478B2
公开(公告)日:2017-05-30
[EN] BENZOTRIAZINE OXIDES AS DRUGS TARGETING MYCOBACTERIUM TUBERCULOSIS<br/>[FR] OXYDES DE BENZOTRIAZINE EN TANT QUE MÉDICAMENTS CIBLANT MYCOBACTERIUM TUBERCULOSIS
申请人:STANFORD RES INST INT
公开号:WO2013086467A1
公开(公告)日:2013-06-13
Benzotriazine doxides are disclosed as drugs targeting mycobacterium tuberculosis, including novel compounds of formula I: (Formula (I)